Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.59 |
| ▸ | ALPL | P05186 | 11/20 | 0.51 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 6/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1455921 | 0.84 | MAPK1 (0.61) | MAPK1ALPLGAAMAPTRAB9A | |
| SCHEMBL5064411 | 0.82 | ALPL (0.51) | ALPLGAAMAPTRAB9APOLB | |
| SCHEMBL27316081 | 0.80 | MAPK1 (0.34) | MAPK1ALPLNOTUM | |
| SCHEMBL16629835 | 0.79 | CHEK1 (0.51) | MAPK1ALPLRAB9APOLBHTT | |
| SCHEMBL24683497 | 0.79 | CFTR (0.41) | MAPK1ALPLGAAMAPTLMNA | |
| SCHEMBL1498674 | 0.78 | ALPL (0.46) | ALPL | |
| SCHEMBL3452780 | 0.78 | DYRK1A (0.34) | MAPK1ALPL | |
| SCHEMBL19223725 | 0.77 | ALPL (0.53) | MAPK1ALPLPOLBSMN1; SMN2 | |
| SCHEMBL2790797 | 0.77 | PLA2G10 (0.41) | ALPLHTT | |
| Hydrochloric Acid SCHEMBL31067451 | 0.77 | ALPL (0.45) | ALPL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 48 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4663189-A2 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | Japan Tobacco Inc. (JP) | 2025-12-17 | — | — | EP | disclosed |
| EP-4116301-B1 | FUSED TRICYCLIC COMPOUND AND MEDICINAL USE THEREOF | JAPAN TOBACCO INC (JP) | 2025-10-08 | — | — | EP | disclosed |
| WO-2025038920-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS, INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| WO-2025038917-A1 | HETEROARYL AMINE COMPOUNDS AND USES THEREOF | XENON PHARMACEUTICALS INC. (CA) | 2025-02-20 | — | — | WO | disclosed |
| CN-115151543-B | Fused tricyclic compounds and medical uses thereof | 日本烟草产业株式会社 | 2024-12-17 | — | — | CN | disclosed |
| EP-4095133-B1 | BENZIMIDAZOLONE-BASED CINNAMAMIDE DERIVATIVE AS TRPV1 ANTAGONIST AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OR PREVENTION OF PAIN CONTAINING SAME AS ACTIVE INGREDIENT | JMACKEM CO LTD (KR) | 2024-07-24 | — | — | EP | disclosed |
| EP-4385984-A1 | PYRIDINE-N-OXIDES AS INHIBITORS OF NAV1.8 | Grünenthal GmbH (DE) | 2024-06-19 | — | — | EP | disclosed |
| US-11999699-B2 | Substituted pyrazole amides | Grünenthal GmbH (DE) | 2024-06-04 | — | — | US | disclosed |
| EP-4355733-A1 | SUBSTITUTED PYRAZOLE AMIDES | Grünenthal GmbH (DE) | 2024-04-24 | — | — | EP | disclosed |
| CN-117460731-A | Heterocyclic lactams, process for their preparation and their use in medicine | 劲方医药科技(上海)有限公司 | 2024-01-26 | — | — | CN | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (US) | 2014-04-24 | — | — | US | disclosed |
| CN-102762534-A | Aryl sulfone derivatives as calcium channel blockers | ZALICUS PHARMACEUTICALS LTD | 2012-10-31 | — | — | CN | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| EP-2477963-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | Zalicus Pharmaceuticals Ltd. (CA) | 2012-07-25 | — | — | EP | disclosed |
| WO-2012061926-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-05-18 | — | — | WO | disclosed |
| WO-2012061926-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-05-18 | — | — | WO | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
| WO-2011035159-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2011-03-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11999699-B2 | Substituted pyrazole amides | SCN8A, SCN1A, SCN7A | MAPK1 1196/4885ALPL 3801/4885GAA 3122/4885 |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | MAPK1 2782/4885ALPL 3458/4885GAA 1394/4885 |
| US-20140113898-A1 | BISARYLSULFONE AND DIALKYLARYLSULFONE COMPOUNDS AS CALCIUM CHANNEL BLOCKERS | CACNA1C, CACNA1S, KCNN4 | MAPK1 3291/4885ALPL 3348/4885GAA 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.